Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022485 | 0.91 | PARP1 (0.44) | PARP1NPC1POLBRAB9ALMNA | |
| SCHEMBL15041959 | 0.89 | MET (0.44) | PARP1 | |
| SCHEMBL13274731 | 0.89 | PARP1 (0.38) | PARP1NPC1POLBRAB9ALMNA | |
| SCHEMBL15022973 | 0.89 | MAPT (0.48) | PARP1NPC1RAB9ALMNAHPGD | |
| SCHEMBL10171290 | 0.88 | MGLL (0.46) | PARP1POLB | |
| SCHEMBL15041960 | 0.85 | HPGD (0.45) | PARP1NPC1RAB9ALMNAHPGD | |
| SCHEMBL15022584 | 0.81 | F10 (0.34) | PARP1ELOVL1 | |
| SCHEMBL12474197 | 0.81 | ENPP2 (0.40) | PARP1NPC1POLBRAB9ALMNA | |
| SCHEMBL12474195 | 0.81 | LMNA (0.43) | LMNAMAPK1 | |
| SCHEMBL13274908 | 0.81 | LMNA (0.38) | PARP1NPC1POLBRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | claimed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MET, ABL1, ERBB2 | PARP1 2443/4885NPC1 4222/4885POLB 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.